Approval · Notice of Compliance 33623 · 2024
ATACAND PLUS: Notice of Compliance 33623
Issued July 11, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33623
- Date
- July 11, 2024
- Company
- Cheplapharm Arzneimittel GmbhGreifswald, Mecklenburg - West Pomerania, Germany
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Administrative: Change in Product Ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATACAND PLUS | 02244021 | Marketed |
| ATACAND PLUS | 02332922 | Marketed |
| ATACAND PLUS | 02332957 | Marketed |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- CANDESARTAN CILEXETIL 16 MG per TAB
- CANDESARTAN CILEXETIL 32 MG per TAB
- HYDROCHLOROTHIAZIDE 25 MG per TAB